$Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436$
Código QR

Código QR

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

We evaluate the risk, characteristics and biomarkers of treatment-emergent cytokine release syndrome (CRS) in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received APVO436 during the dose-escalation phase of a Phase 1B study (ClinicalTrials.gov...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fatih M. Uckun, Justin Watts, Alice S. Mims, Prapti Patel, Eunice Wang, Paul J. Shami, Elizabeth Cull, Cynthia Lee, Christopher R. Cogle, Tara L. Lin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	AML CD123 bispecific antibody T-cells leukemia clinical study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/06dabbe623364c4d83e5d999b62b3aa2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
por: Pan H, et al.
Publicado: (2018)

CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells
por: Wariya Nirachonkul, et al.
Publicado: (2021)

Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment
por: Guo D, et al.
Publicado: (2020)

Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
por: Madhu S. Pandey, et al.
Publicado: (2021)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
por: Franziska Brauneck, et al.
Publicado: (2021)

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor
por: Elisa C. Toffoli, et al.
Publicado: (2021)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Huicheng Liu, et al.
Publicado: (2021)

Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
por: Shakeri S., et al.
Publicado: (2021)

Seminario Derecho laboral régimen de subcontratación ley n.º 20.123
Publicado: (2006)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Fatih M. Uckun, et al.
Publicado: (2021)

Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
por: Christina L. Parker, et al.
Publicado: (2020)

A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia
por: Shilin Xu, et al.
Publicado: (2021)

4,5-Dicyano-1,2,3-Triazole—A Promising Precursor for a New Family of Energetic Compounds and Its Nitrogen-Rich Derivatives: Synthesis and Crystal Structures
por: Wenli Cao, et al.
Publicado: (2021)

Frecuencia de los genes de fusión TEL/AML1 y BCR/ABL en pacientes pediátricos con leucemia linfoblástica aguda
por: Artigas A,Carmen Gloria, et al.
Publicado: (2006)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Xiaopei Cui, et al.
Publicado: (2021)

Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein
por: Chen H, et al.
Publicado: (2018)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Daisuke Kamakura, et al.
Publicado: (2021)

Synthesis, crystal structure and Hirshfeld surface analysis of (4-methylphenyl)[1-(pentafluorophenyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl]methanone
por: Nazariy T. Pokhodylo, et al.
Publicado: (2021)

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Donata Backhaus, et al.
Publicado: (2021)

Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
por: Aleksandra Rodak, et al.
Publicado: (2021)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
por: Ana Rio-Machin, et al.
Publicado: (2020)

Tumour‐derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8‐mediated creatine import in NPM1‐mutated acute myeloid leukaemia
por: Meixi Peng, et al.
Publicado: (2021)

CSF1R Inhibition Combined with GM-CSF Reprograms Macrophages and Disrupts Protumoral Interplays with AML Cells
por: Tatiana Smirnova, et al.
Publicado: (2021)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
por: Mark A.J.M. Hendriks, et al.
Publicado: (2021)

Legacy 1,2,3-trichloropropane contamination: a systematic review of treatments
por: B. Hope Hauptman, et al.
Publicado: (2021)

Lotus 1-2-3 versiones 2.3 y 2.4 para DOS, consulta instantánea
por: Robbins, Judd
Publicado: (1993)

1-2-3 en el mundo de la estadística
por: Person, Ron
Publicado: (1992)

Lotus 1-2-3 versión 2.3, consulta instantánea
por: Robbins, Judd
Publicado: (1992)

Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
por: Varbanova V., et al.
Publicado: (2020)

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
por: Meredith E. Davis-Gardner, et al.
Publicado: (2020)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Hagop M. Kantarjian, et al.
Publicado: (2021)

Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity
por: Cheng WJ, et al.
Publicado: (2021)

Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
por: Lim MY, et al.
Publicado: (2014)

Aplicaciones del Lotus 1-2-3: modelos financieros, incluye versión 2
por: Kyd, Charles W
Publicado: (1988)

NEW APPROACHES FOR THE SYNTHESIS OF HYDRAZONE DERIVATIVES AND THEIR ANTITUMOR EVALUATION
por: WARDAKHAN,WAGNAT WAHBA, et al.
Publicado: (2012)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
por: Chiricozzi A, et al.
Publicado: (2019)

Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Publicado: (2021)

Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression
por: Marie-Theresa Weickert, et al.
Publicado: (2021)

Acta Nº436
por: Banco Central de Chile
Publicado: (2019)

Enfermedad granulomatosa crónica. Diagnóstico mediante el ensayo de dihidrorodamina
por: Sanabria,Diana, et al.
Publicado: (2020)